Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live

United States & Amgen

13 shared events · Importance 3 · Last updated Sep 04, 2026

Importance
3
Shared Events
13
Actions
0
Sentiment
0
Live sentiment trends, interaction importance charts, and action volume tracking available on the Ergen Dashboard
69
Business
United States: The US is part of North America, which held the largest market share in 2025, supported by strong regulatory frameworks and advanced manufacturing.
Amgen: Amgen is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
63
Domestic
United States: The U.S. government, through the United States — White House, negotiated the drug pricing deals to lower costs for patients and reduce federal spending. The agreements are part of a broader push to make healthcare more affordable.
Amgen: Amgen was among the earlier drugmakers that signed MFN deals, helping establish the framework now extended to nine more companies.
Aug 18, 2026 · 37 articles
45
Accidents
United States: US regulators may investigate the breach and enforce data protection laws, potentially imposing fines on Amgen.
Amgen: Amgen is the primary victim, facing potential regulatory fines, legal liabilities, and reputational damage from the breach. The company is managing the incident and assessing the full scope of data exposure.
Jul 31, 2026 · 6 articles
40
Business
United States: The United States is a key market for Tezspire, where eosinophilic esophagitis affects over 470,000 people. The trial success could lead to expanded approval and market access.
Amgen: Amgen co-developed Tezspire and shares in its sales. The positive trial outcome is favorable for Amgen's respiratory portfolio, potentially enhancing its market position.
Aug 27, 2026 · 6 articles
31
International
United States: The US is a key stakeholder, having blockaded Iranian ports and opposed Iranian control. A deal could reduce oil prices and political pressure, but may be seen as a concession.
Amgen: Amgen's stock rose on strong sales, contributing to the Dow's gains. It is unrelated to the Hormuz situation.
Mar 09, 2018 · 316 articles
24
Business
United States: The U.S. government announced a $2 billion initiative to take equity stakes in quantum computing companies, including a $100 million investment in Quantinuum, boosting sentiment for the sector and highlighting its strategic importance.
Amgen: Amgen Inc. is an early user and collaborator with Quantinuum, demonstrating the practical application of Quantinuum's quantum computing platforms.
May 26, 2026 · 76 articles
22
Tech
United States: The study was conducted in 27 sites across the United States, and its findings have significant implications for public health and healthcare spending within the nation.
Amgen: One author disclosed ties to Amgen, which is a minor detail in the context of the overall study findings.
Jun 15, 2026 · 6 articles
22
Business
United States: The United States>>> is the target market for the biosimilar applications, with the United States — Food and Drug Administration>>> (FDA) being the regulatory authority for approval.
Amgen: Amgen>>> owns the trademarks for Prolia and Xgeva, the reference products for Alvogen>>>'s AVT03 biosimilar. While not directly related to the current resubmissions, it highlights the competitive landscape Alvogen>>> operates in.
Jun 04, 2026 · 10 articles
20
Business
United States: The United States is the regulatory and market jurisdiction for the IPO, with the SEC and Nasdaq based there.
Amgen: Amgen's Repatha is a competitor to Scribe's STX-1150 in the PCSK9 inhibitor space. The success of Scribe's therapy could impact Amgen's market share in cholesterol management.
Jul 06, 2026 · 25 articles
17
Regulatory
United States: The United States, through the FDA, approved the drug, making it available to American patients and potentially influencing global regulatory decisions.
Amgen: Amgen, a competitor with an approved KRAS G12C inhibitor, may face increased competition but also benefits from validation of the RAS-targeting approach.
Aug 26, 2026 · 92 articles
0
Regulatory
Dec 19, 2025 · 7 articles
0
Regulatory
May 08, 2026 · 6 articles
0
Tech
Jun 12, 2026 · 7 articles
ERGEN INTELLIGENCE
Explore this relationship live

Track how United States and Amgen interact across events, view sentiment trends, and discover connected entities.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.